tirzepatide and statins Association of Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score–Matched Real-World Study Tirzepatide vs. Retatrutide: Key Differences
Description
10.1016/j.jand.2018.03.007 [EL 4
Key results The results were dose-dependent and remarkable at every level: 1mg: Approximately 8.7% weight loss 4mg: Approximately 17.1% weight loss 8mg: Approximately 22.8% weight loss 12mg: Approximately 24.2% weight loss Placebo: Approximately 2.1% weight loss The 24.2% weight loss at 12mg over 48 weeks was unprecedented
The continuation group kept losing, net negative 17.4 percent from baseline
It helps me eat smaller portion and not crave junk food
An ingredient may be combined, mixed, or altered in order to make a drug specifically tailored to an individual patient
